Literature DB >> 28210770

The "reset button" revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.

Frederik A Verburg1, Markus Luster2, Luca Giovanella3, Michael Lassmann4, Carlo Chiesa5, Nicolas Chouin6, Glenn Flux7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28210770     DOI： 10.1007/s00259-017-3649-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  21 in total

1.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.

Authors:  C Bal; A K Padhy; S Jana; G S Pant; A K Basu
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

2.  Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.

Authors:  Désirée Deandreis; Carole Rubino; Hernan Tala; Sophie Leboulleux; Marie Terroir; Eric Baudin; Steve Larson; James A Fagin; Martin Schlumberger; R Michael Tuttle
Journal:  J Nucl Med       Date:  2016-10-13       Impact factor: 10.057

3.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

Review 4.  The use of dosimetry in the treatment of differentiated thyroid cancer.

Authors:  M Lassmann; H Hänscheid; F A Verburg; M Luster
Journal:  Q J Nucl Med Mol Imaging       Date:  2011-04       Impact factor: 2.346

5.  Approach to the patient: role of dosimetric RAI Rx in children with DTC.

Authors:  Frederik A Verburg; Christoph Reiners; Heribert Hänscheid
Journal:  J Clin Endocrinol Metab       Date:  2013-10       Impact factor: 5.958

6.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

7.  Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.

Authors:  Frederik A Verburg; Uwe Mäder; Karina Tanase; Elena-Daphne Thies; Stefanie Diessl; Andreas K Buck; Markus Luster; Christoph Reiners
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

8.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236

9.  124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.

Authors:  L S Freudenberg; W Jentzen; R Görges; T Petrich; R J Marlowe; J Knust; A Bockisch
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

10.  Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

Authors:  Frederik A Verburg; Heribert Hänscheid; Johannes Biko; Maria C Hategan; Michael Lassmann; Michael C Kreissl; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-24       Impact factor: 9.236
View more
  5 in total

Review 1.  Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches.

Authors:  Makoto Hosono
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

2.  The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy.

Authors:  C Chiesa; K Sjogreen Gleisner; G Flux; J Gear; S Walrand; K Bacher; U Eberlein; E P Visser; N Chouin; M Ljungberg; M Bardiès; M Lassmann; L Strigari; M W Konijnenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-24       Impact factor: 9.236

3.  Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.

Authors:  Kevin Zwirtz; Juliane Hardt; Güliz Acker; Alexander D J Baur; Marianne Pavel; Kai Huang; Winfried Brenner; Vikas Prasad
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

4.  Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.

Authors:  Mohammad Abuqbeitah; Mustafa Demir; İffet Çavdar; Handan Tanyildizi; Nami Yeyin; Lebriz Uslu-Beşli; Levent Kabasakal; Nazenin İpek Işıkcı; Kerim Sönmezoğlu
Journal:  Radiat Environ Biophys       Date:  2018-10-08       Impact factor: 1.925

Review 5.  Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer.

Authors:  Massimiliano Pacilio; Miriam Conte; Viviana Frantellizzi; Maria Silvia De Feo; Antonio Rosario Pisani; Andrea Marongiu; Susanna Nuvoli; Giuseppe Rubini; Angela Spanu; Giuseppe De Vincentis
Journal:  Diagnostics (Basel)       Date:  2022-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.